AU2001279775A1 - Medicament for the immunotherapy of malignant tumours - Google Patents

Medicament for the immunotherapy of malignant tumours

Info

Publication number
AU2001279775A1
AU2001279775A1 AU2001279775A AU7977501A AU2001279775A1 AU 2001279775 A1 AU2001279775 A1 AU 2001279775A1 AU 2001279775 A AU2001279775 A AU 2001279775A AU 7977501 A AU7977501 A AU 7977501A AU 2001279775 A1 AU2001279775 A1 AU 2001279775A1
Authority
AU
Australia
Prior art keywords
medicament
immunotherapy
malignant tumours
tumors
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001279775A
Other languages
English (en)
Inventor
Armin Grossmann
Klaus-Dieter Rockensuss
Claudia Ulbrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LIPONOVA GmbH
Original Assignee
LIPONOVA GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LIPONOVA GmbH filed Critical LIPONOVA GmbH
Publication of AU2001279775A1 publication Critical patent/AU2001279775A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001279775A 2000-07-28 2001-07-21 Medicament for the immunotherapy of malignant tumours Abandoned AU2001279775A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00116362 2000-07-28
EP00116362 2000-07-28
PCT/EP2001/008455 WO2002009745A1 (de) 2000-07-28 2001-07-21 Arzneimittel zur immuntherapie maligner tumoren

Publications (1)

Publication Number Publication Date
AU2001279775A1 true AU2001279775A1 (en) 2002-02-13

Family

ID=8169380

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001279775A Abandoned AU2001279775A1 (en) 2000-07-28 2001-07-21 Medicament for the immunotherapy of malignant tumours

Country Status (20)

Country Link
US (2) US20030129206A1 (pt)
EP (1) EP1305041B1 (pt)
JP (1) JP2004505058A (pt)
AT (1) ATE330626T1 (pt)
AU (1) AU2001279775A1 (pt)
BG (1) BG107482A (pt)
CA (1) CA2417374A1 (pt)
CY (1) CY1105179T1 (pt)
CZ (1) CZ299669B6 (pt)
DE (1) DE50110274D1 (pt)
DK (1) DK1305041T3 (pt)
ES (1) ES2267800T3 (pt)
HK (1) HK1055562A1 (pt)
HU (1) HUP0300772A3 (pt)
NO (1) NO20030420L (pt)
PL (1) PL358675A1 (pt)
PT (1) PT1305041E (pt)
SI (1) SI1305041T1 (pt)
SK (1) SK822003A3 (pt)
WO (1) WO2002009745A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211971A1 (en) * 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
KR20050109498A (ko) * 2003-02-20 2005-11-21 유니버시티 오브 코네티컷 헬스 센터 암 또는 전염병 치료에서 열 충격 단백질 또는알파-2-마크로글로불린을 포함하는 조성물을 사용하는 방법
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
MY160857A (en) * 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
EP1974742A1 (en) * 2007-03-29 2008-10-01 LipoNova AG A method for improving the manufacturing process of a tumour vaccine
CN102470167A (zh) 2009-07-02 2012-05-23 Ith免疫治疗控股公司 基于外泌体的癌症治疗
CN105807053B (zh) 2016-04-15 2019-04-02 苏州药明康德新药开发股份有限公司 一种肿瘤解离试剂在流式细胞检测中的应用
ES2908885T3 (es) 2017-07-05 2022-05-04 Vcc Medical Deutschland Gmbh Método para fabricar una vacuna tumoral

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
DE19633731A1 (de) * 1996-08-21 1998-02-26 Johann Hinrich Prof Dr Peters Hybridzellen zur Steigerung der Immunogenität von Tumorzellen
WO1999042564A2 (en) * 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
DE19812004A1 (de) * 1998-03-19 1999-09-30 Forschungszentrum Juelich Gmbh Dehydrogenasen mit verbesserter NAD-Abhängigkeit, deren Herstellung und Verwendung
EP1064390A4 (en) * 1998-03-20 2002-06-12 Genzyme Corp IMPROVED ANTI-TUMOR IMMUNITY
CA2326739A1 (en) * 1998-04-02 1999-10-14 The Regents Of The University Of California Methods for enhancing antigen-presenting cells and anti-tumor responses in a human patient
US6045990A (en) * 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature

Also Published As

Publication number Publication date
HUP0300772A3 (en) 2005-11-28
SI1305041T1 (sl) 2006-12-31
DE50110274D1 (de) 2006-08-03
CY1105179T1 (el) 2010-03-03
PL358675A1 (en) 2004-08-09
EP1305041A1 (de) 2003-05-02
HUP0300772A2 (en) 2003-08-28
JP2004505058A (ja) 2004-02-19
US20030129206A1 (en) 2003-07-10
DK1305041T3 (da) 2006-10-23
NO20030420D0 (no) 2003-01-27
EP1305041B1 (de) 2006-06-21
US20070134275A1 (en) 2007-06-14
BG107482A (bg) 2003-11-28
CZ299669B6 (cs) 2008-10-08
HK1055562A1 (en) 2004-01-16
PT1305041E (pt) 2006-09-29
ES2267800T3 (es) 2007-03-16
NO20030420L (no) 2003-01-27
CZ2003179A3 (cs) 2004-01-14
WO2002009745A1 (de) 2002-02-07
ATE330626T1 (de) 2006-07-15
SK822003A3 (en) 2004-05-04
CA2417374A1 (en) 2003-01-27

Similar Documents

Publication Publication Date Title
YU23202A (sh) Lekovi za tretman malignih tumora
IL148782A0 (en) Drugs for the treatment of malignant tumours
AU2001233726A1 (en) Farnesyl protein transferase inhibitors for treating breast cancer
AU9660801A (en) Compositions and methods for wt1 specific immunotherapy
SE9901875D0 (sv) Novel compounds
MXPA05011755A (es) Composiciones y metodos para inmunoterapia especifica de tumor wilms 1.
WO2007038868A3 (en) Novel enediyne compound and uses thereof
MY128924A (en) Novel compounds
HK1040983A1 (en) Quinones for treatment of diseases.
AU6369900A (en) Aromatic esters of camptothecins and methods to treat cancers
CY1105179T1 (el) Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων
WO2000061756A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO2001035989A3 (de) Verwendung von anti-idiotypische antikörpern als impfstoffe gegenkrebs
TW200504051A (en) Novel acridine derivatives and their use as medicaments
BR0008305A (pt) Utilização de uma proteìna ompa de enterobactéria, ou de um de seus fragmentos e composição farmacêutica
MX2010004332A (es) Esteres de camptotecina cristalinos hidratados para el tratamiento de cancer.
AU2002352011A1 (en) Immunogenic alk (anaplastic lymphoma kinase) peptides
UA87292C2 (ru) Применение сирамезина для лечения злокачественных опухолей
WO2003035104A3 (en) Compositions and methods for selected tumor treatment
AU2001256440A1 (en) Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent
UA49216A (uk) Засіб для лікування ускладнень після видалення злоякісних новоутворень шкіри
DE60235085D1 (de) Herstellungsverfahren von derivate von bisphosphonaten
WO2001048205A3 (en) Murine neu sequences and methods of use therefor
MX9700398A (es) Solucion para la modificacion de tumores cancerosos.
AU2003251446A1 (en) Formulation of liposomal derivatives of phenylalanine